Evercore ISI Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Alnylam Pharma, with a price target of $515.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Kasimov is a 5-star analyst with an average return of 15.9% and a 55.19% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Zenas BioPharma, Inc., Moderna, and Neurocrine.
In addition to Evercore ISI, Alnylam Pharma also received a Buy from Bank of America Securities’s Tazeen Ahmad in a report issued yesterday. However, today, TipRanks – Google reiterated a Hold rating on Alnylam Pharma (NASDAQ: ALNY).
Based on Alnylam Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.25 billion and a net profit of $251.08 million. In comparison, last year the company earned a revenue of $500.92 million and had a GAAP net loss of $111.57 million
Read More on ALNY:
Disclaimer & DisclosureReport an Issue
- Alnylam: Near-Term Amvuttra Shortfall Outweighed by Robust TTR Growth Outlook and Strengthened Long-Term Leadership Position
- Alnylam Pharmaceuticals: Strong Long-Term Growth Strategy But Balanced Risk/Reward Supports Hold Rating
- Alnylam 2026 guidance reflects continued momentum, says H.C. Wainwright
- Alnylam price target raised to $529 from $520 at Needham
- Alnylam price target lowered to $529 from $530 at BofA
